Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Professor Wael Jaber,
This was the first joint session to be held at this meeting that is co-sponsored by the American Society of Nuclear Cardiology (ASNC). The 4 speakers addressed all recent cardiac imaging-related trials with focus on clinical implications in daily practice. The session took a tour de force by Dr. Danilo Neglia from a leading Italian European trial (EVINCI), to a review of COURAGE and PROMISE and a new risk score by Dr. Cremer that can outperform the Forester-Diamond score. In addition, we learned about the value and downstream course of testing from a presentation from the CE-MARC 1 and 2 studies. The 2 studies used SPECT, and perfusion MRI or later a NICE-guided management for patients presenting with possible coronary disease. Finally, we had a review by Dr Thomas of the STICH and PARR-2 studies and their role in guiding viability testing. We learned the major shortcomings of STICH as an observational non-randomised “viability” trial utilising an outdated and inconsistent testing modality in an open label fashion, and in some but not all patients in the overall study. The chairs and the speakers all agreed that optimal medical therapy should be the initial management of patients with suspected or confirmed coronary artery disease. Any future trial should include an optimal medical therapy arm in addition to the imaging arm(s).
© 2017 European Society of Cardiology. All rights reserved